These biomarkers are crucial for personalized medicine because they help identify which patients are most likely to benefit from immune checkpoint inhibitors, a class of drugs that block these checkpoints. By tailoring treatment plans based on the presence or absence of specific biomarkers, oncologists can improve treatment efficacy and reduce unnecessary side effects.
